Supercharged immune cells aim to stop cancer relapse after transplant

NCT ID NCT03533816

First seen Mar 27, 2026 · Last updated May 16, 2026 · Updated 6 times

Summary

This study is for people with certain blood cancers (like leukemia) who are getting a half-matched bone marrow transplant. Researchers are adding a dose of specially grown immune cells (gamma delta T-cells) after the transplant to see if it can kill any leftover cancer cells while reducing the risk of graft-versus-host disease, a common complication. The trial is in its early phase, testing safety and the right dose in about 38 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ohio State University Medical Center

    RECRUITING

    Columbus, Ohio, 43210-1238, United States

  • University of Kansas Cancer Center

    RECRUITING

    Westwood, Kansas, 66205, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.